October 14, 2024
Sector earnings or LPS (loss-per-share) season is just ahead …
Pre-open indications: 3 Positive and 4 Negative Indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninform
October 15, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
2 to report ... so far:
Sage Therapeutics (SAGE) 10/29 Tuesday
MiMedx (MDXG) 10/30 Wednesday
October 15, 2024
Sector tuned positive late in the session after a neutral start and with a negative dive then an out-of-the-blue positive close
As Q3 earnings season is about to begin, uncertainty looms, raising questions about its impact on share pricing performance
Never leave an investor uninformed!
The week in review
October 15, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 2 to report ... so far: Sage Therapeutics (SAGE) 10/29 Tuesday MiMedx (MDXG) 10/30 Wednesday
October 3, 2024
Called “Monetization Financing with DRI Healthcare Trust” as access to capital markets is shaky EDIT sold certain future license fees and other payments owed under its Cas9 license agreement with Vertex Pharmaceuticals (VRTX)to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. EDIT closed down -$0.02 with only a +$0.06 or +1.87% aftermarket indication
September 10, 2024
Priced at $43.50 of 11.5 M shares IONS closed up +$1.44 or +3.07 M to $48.03 with a negative -$5.94 to $42.39 on Tuesday Check-out debt versus cash (below) Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering